Here's Why You Should Retain Globus Medical (GMED) Stock Now
https://www.zacks.com/stock/news/2240217/here-s-why-you-should-retain-globus-medical-gmed-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240217
Mar 13, 2024 - Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
0
AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex
https://www.zacks.com/stock/news/2240143/amn-healthcare-amn-expands-capabilities-of-shiftwise-flex?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240143
Mar 13, 2024 - AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.
0
BD's (BDX) ADC System Favored by New Study for Long-Term Care
https://www.zacks.com/stock/news/2240879/bd-s-bdx-adc-system-favored-by-new-study-for-long-term-care?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240879
Mar 14, 2024 - BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
0
Charles River (CRL) Extends Gene Therapy Offering With New Pact
https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241549
Mar 15, 2024 - Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
0
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
https://www.zacks.com/stock/news/2242295/revvity-s-rvty-new-launch-to-boost-newborn-sequencing-research?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242295
Mar 18, 2024 - Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
0
Labcorp (LH) Presents New Research on Precision Diagnostics
https://www.zacks.com/stock/news/2242254/labcorp-lh-presents-new-research-on-precision-diagnostics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242254
Mar 18, 2024 - Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
0
Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100
https://www.zacks.com/stock/news/2243024/inspira-technologies-iinn-strives-to-get-amar-nod-for-art100?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243024
Mar 19, 2024 - The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
0
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
https://www.zacks.com/stock/news/2242630/here-s-why-you-should-retain-tandem-diabetes-tndm-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242630
Mar 19, 2024 - Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
0
Here's Why Investors Should Retain Abbott (ABT) Stock Now
https://www.zacks.com/stock/news/2243034/here-s-why-investors-should-retain-abbott-abt-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2243034
Mar 19, 2024 - Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
0
Here's Why You Should Retain HealthEquity (HQY) Stock Now
https://www.zacks.com/stock/news/2242869/here-s-why-you-should-retain-healthequity-hqy-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242869
Mar 19, 2024 - HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
0